B. Riley Issues Negative Forecast for CAPR Earnings

Capricor Therapeutics, Inc. (NASDAQ:CAPR) – Investment analysts at B. Riley decreased their Q3 2025 earnings per share estimates for shares of Capricor Therapeutics in a report issued on Tuesday, August 12th. B. Riley analyst M. El-Saadi now forecasts that the biotechnology company will post earnings per share of ($0.47) for the quarter, down from their previous estimate of ($0.46). B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share. B. Riley also issued estimates for Capricor Therapeutics’ Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.85) EPS and FY2027 earnings at ($0.38) EPS.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Monday, August 11th. The biotechnology company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). Capricor Therapeutics had a negative return on equity of 62.71% and a negative net margin of 181.71%.

A number of other equities research analysts have also recently commented on CAPR. Jones Trading lowered their target price on Capricor Therapeutics from $40.00 to $29.00 and set a “buy” rating on the stock in a research note on Wednesday, June 25th. Oppenheimer lowered their target price on Capricor Therapeutics from $43.00 to $22.00 and set an “outperform” rating on the stock in a research note on Monday, June 23rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $30.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. Piper Sandler restated an “overweight” rating and issued a $20.00 price objective on shares of Capricor Therapeutics in a research note on Friday, July 11th. Finally, Roth Capital lowered their price objective on Capricor Therapeutics from $31.00 to $12.00 and set a “buy” rating on the stock in a research note on Monday, July 14th. One research analyst has rated the stock with a sell rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $22.56.

Capricor Therapeutics Price Performance

NASDAQ CAPR opened at $7.96 on Friday. The stock has a market capitalization of $363.91 million, a price-to-earnings ratio of -4.85 and a beta of 0.59. Capricor Therapeutics has a one year low of $3.84 and a one year high of $23.40. The business’s fifty day moving average is $9.17 and its 200-day moving average is $10.99.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Summit Investment Advisors Inc. grew its holdings in Capricor Therapeutics by 54.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in Capricor Therapeutics by 172.8% during the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 2,947 shares in the last quarter. Virtus ETF Advisers LLC purchased a new position in Capricor Therapeutics during the 4th quarter valued at about $68,000. Tower Research Capital LLC TRC grew its holdings in Capricor Therapeutics by 280.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after buying an additional 4,976 shares in the last quarter. Finally, Citizens Financial Group Inc. RI purchased a new position in Capricor Therapeutics during the 1st quarter valued at about $95,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.